Table 2 Antitumour activity

From: A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer

 

All patientsa (n =45)

History of previous adjuvant chemotherapy

   

Yes ( n =9)

No ( n =36)

Response

No.

(%)

No.

(%)

No.

(%)

CR

2

4.4

1

11.1

1

2.8

PR

20

44.5

2

22.2

18

50.0

SD

15

33.3

6

66.7

9

25.0

PD

6

13.3

0

0

6

16.7

NAb

2

4.4

0

0

2

5.6

  1. aIntention-to-treat analysis.
  2. bNot assessable.